Camelina oil

Camelina Oil: A Comprehensive Reference

1. Identity and Botanical Description

Botanical and Scientific Names

Camelina sativa (L.) Crantz — known in English as camelina, gold-of-pleasure, false flax, wild flax, linseed dodder, German sesame, and Siberian oilseed — is a flowering plant in the family Brassicaceae, which includes mustard, cabbage, rapeseed, broccoli, cauliflower, kale, and Brussels sprouts. An older synonym also found in the literature is Myagrum sativum. The genus name Camelina appears to be derived from two Greek words meaning "on the ground" or "dwarf" and "flax" — that is, "Dwarf Flax." The Latin specific epithet sativa means "planted" or "cultivated."

Natural Source and Morphology

Camelina is native to Northern Europe and to Central Asia, but has been introduced to North America, possibly as a weed in flax imports. As a summer or winter annual plant, camelina grows to heights of 30–120 cm (12–47 in), with branching stems that become woody at maturity. The leaves are alternate on the stem, and lanceolate with a length from 2–8 cm and a width of 2–10 mm. The plant belongs to the same family as many economically important crops, making it agronomically familiar and relatively straightforward to cultivate with conventional equipment.

Common Forms and Preparations

The primary commercial product derived from camelina is a cold-pressed, unrefined seed oil obtained by mechanical pressing of the small seeds. Unrefined oils are yellow to golden-yellow in color, while refined oils are colorless to mild yellow. It has an almond-like flavor and aroma. Camelina oil is available as a cold-pressed culinary oil, as dietary supplement capsules or liquid oil, as a topical/cosmetic ingredient, and incorporated into functional foods. Seeds themselves can also be used in cooking and in foods such as salads, porridge, muesli, and smoothies. The oil is registered under the name "Olej rydzowy tradycyjny" ("traditional Camelina oil" in Polish) as a Traditional Speciality Guaranteed product in the European Union and the United Kingdom.

2. Traditional and Historical Use

Ancient Cultivation

Camelina sativa has been traditionally cultivated as an oilseed crop to produce vegetable oil and animal feed, and ample archaeological evidence shows it has been grown in Europe for at least 3,000 years. The earliest archaeological sites where it was found include the Neolithic levels at Auvernier, Switzerland (dated to the second millennium BC), the Chalcolithic level at Pefkakia in Greece (dated to the third millennium BC), and Sucidava-Celei, Romania (circa 2200 BC). During the Bronze Age and Iron Age, it was an important agricultural crop in northern Greece, beyond the current range of the olive.

Spread Through Europe

Camelina's centers of origin are Southwest Asia and Southeast Europe; around 2000 BC during the Bronze Age, it was domesticated in the southeast of Europe, and the plant was grown all over Europe during the Iron Age. During the Bronze Age, it came as a cultivated plant to southern and central Scandinavia and Finland. Camelina spread through other parts of Europe in its early history, with remnants of the seeds pressed for their oil being found in Iron Age and Viking archaeological sites in Northern Europe.

Traditional Uses

Native to Europe and Central Asia, camelina has been cultivated for at least 3,000 years for its high-quality seed oil, which was once a staple in cooking, lamp fuel, and later lubricants and biofuels. People also used camelina as a medicine to treat wounds, burns, and infections, but demand for camelina greatly reduced in the Industrial Age, and by 1929, production in Sweden had completely stopped. Historically, its oil was used for cooking and fuel, and the meal was fed to livestock; camelina production in Europe and Russia was replaced in large part by canola in the mid-1900s, as canola proved easier to hydrogenate.

In Eastern Europe, traditional use of camelina oil continues in rural diets, while in modern markets it is sold as a cold-pressed culinary oil rich in omega-3s. Camelina was farmed in Europe and Russia until the mid-1900s to produce oil. The oil's Renaissance in recent decades has been driven by renewed interest in its nutritional profile, its agronomic resilience, and its potential as a biofuel feedstock.

3. Key Constituents and Active Compounds

Fatty Acid Profile

Camelina oil is largely unsaturated (greater than 90%), high in both omega-3 and omega-6 fatty acids; the total amount of omega-3 fatty acids is approximately 39% (with 38% alpha-linolenic acid), and the total amount of omega-6 fatty acids is approximately 18% (with 17% linoleic acid).

The fatty acid composition of camelina comprises high levels of polyunsaturated fatty acids, such as C18:2 and C18:3 fatty acids (52–54%), as well as long-chain fatty acids, such as C20:1 (11–15%) and C22:1 (2–5%) fatty acids. The major components are alpha-linolenic acid (ALA) — C18:3, an omega-3 fatty acid at approximately 35–45% — and linoleic acid — C18:2, an omega-6 fatty acid, at approximately 15–20%. It contains 1–3% erucic acid. Oleic acid (C18:1, an omega-9 fatty acid) is present at lower concentrations, while gondoic acid (C20:1, eicosenoic acid) constitutes another notable long-chain monounsaturated component.

Tocopherols (Vitamin E)

The oil is very rich in natural antioxidants, such as tocopherols, making this highly stable oil very resistant to oxidation and rancidity. The vitamin E content of camelina oil is approximately 110 mg/100 g. Gamma-tocopherol (14.30 mg/100 g seed) was identified as the major isomer, followed by α-tocopherol (1.75 mg/100 g seed) and β-tocopherol (1.0 mg/100 g seed). The high tocopherol content is significant because it contributes to the oil's oxidative stability, distinguishing it from other polyunsaturated-rich oils such as flaxseed oil that are comparatively less stable.

Minor Bioactive Constituents

Camelina oil also contains phytosterols and other minor lipid-soluble constituents. Glucosinolates and erucic acid (cis 13-22:1) are the major anti-nutrient compounds present in camelina, with concerns related to their effects on the thyroid gland and the cardiovascular system. These constituents are discussed in greater detail in the safety section below.

Nutritional Summary Table

• Alpha-linolenic acid (ALA, C18:3n-3, omega-3): ~35–45% of fatty acids
• Linoleic acid (LA, C18:2n-6, omega-6): ~15–20% of fatty acids
• Oleic acid (C18:1n-9, omega-9): minor fraction, typically ~14–17%
• Gondoic acid (C20:1): ~11–15% of fatty acids
• Erucic acid (C22:1): ~1–3% of fatty acids
• Total polyunsaturated fatty acids: >50% of total fatty acids
• Vitamin E (tocopherols): ~110 mg/100 g oil

4. Mechanisms of Action

Alpha-Linolenic Acid as Primary Bioactive Agent

The predominant proposed mechanism of action for camelina oil's health effects centers on its high ALA content. Oils rich in alpha-linolenic acid have gained attention due to the expected cardioprotective health benefits associated with this fatty acid; ALA is the metabolic precursor of the long-chain polyunsaturated fatty acids EPA and DHA, although this conversion happens at low rates. Dietary ALA can be slowly metabolized into eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3), with an efficiency of only a few percent; however, the bulk of ALA metabolites is used to synthesize anti-inflammatory series of prostaglandins and leukotrienes.

Eicosanoid Modulation

Linoleic acid is converted into arachidonic acid (AA), and ALA is converted into eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); both AA and EPA/DHA are parent compounds for the production of pro- and anti-inflammatory eicosanoids, respectively. The eicosanoids produced from the n-6-derived arachidonic acid have a different physiological effect than those produced from n-3-derived EPA and DHA; more AA results in pro-inflammatory effects, whereas more EPA and DHA result in resolvins, which are anti-inflammatory and pro-resolving.

Lipid Metabolic Gene Expression

Camelina oil has been suggested to modulate fatty acid synthesis and oxidation through the upregulation of β-oxidation gene expression, such as peroxisome proliferator-activated receptor α (PPARα) and carnitine palmitoyltransferase-1 (CPT-1); furthermore, it has also been proposed to inhibit lipogenic gene expression, such as sterol regulatory element binding proteins (SREBPs), carbohydrate-responsive element-binding protein and PPARγ.

Membrane Incorporation and Serum Fatty Acid Enrichment

In human hypercholesterolemic subjects, the proportion of ALA in fatty acids of serum lipids was significantly higher in the camelina group — 2.5 times higher compared to the rapeseed oil group and 4 times higher compared to the olive oil group — at the end of a 6-week intervention. Respectively, the proportions of two metabolites of alpha-linolenic acid — eicosapentaenoic and docosapentaenoic acids — also increased and differed significantly in the camelina group from those in other groups. This serum fatty acid enrichment is considered a biomarker of ALA bioavailability and a mechanistic pathway toward downstream health effects.

Skin: ALA in Membrane Structure

Alpha-linolenic acid is a minor physiological component of cellular and mitochondrial membranes that regulates cell signaling and transport across the lipid bilayers. Both alpha-linolenic acid and linoleic acid reduce UV-associated damage and hyperpigmentation of the skin.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Lipid Profile

This is the most extensively studied area for camelina oil in human subjects. A systematic review and dose-response meta-analysis, searching ISI Web of Science, PubMed, and Scopus databases up to July 2022, selected seven eligible RCTs including 428 individuals; interventions of less than 2 weeks, those without a placebo group, or those combining camelina oil with another supplement were excluded, and weighted mean differences were pooled using a random-effects model.

The overall pooled results were nuanced. Data analysis from six trials that evaluated the lipid profile showed that camelina oil supplementation did not significantly change LDL (−3.16 mg/dl), HDL (0.41 mg/dl), total cholesterol (−4.06 mg/dl), or triglycerides (−4.92 mg/dl) compared to the control group. However, subgroup analysis revealed important modifiers: the pooled analysis revealed that camelina oil supplementation significantly improved total cholesterol in studies lasting more than 8 weeks and utilizing dosages lower than 30 g/d compared to the placebo group. The results of fractional polynomial modeling indicated nonlinear dose-response relations between the dose and absolute mean differences in LDL, HDL, and total cholesterol (but not triglycerides), and it appears that the greatest effect occurs at the dosage of 20 g/day.

The meta-analysis concluded that camelina oil supplementation may reduce cardiovascular disease risk by improving lipid profile markers, and that dosages lower than 30 g/d may be a beneficial nonpharmacological strategy for lipid control; however, further RCTs with longer durations are warranted.

One of the earliest human RCTs was published in 2002 in Metabolism. Sixty-eight hypercholesterolemic subjects aged 28 to 65 years were randomly assigned after a 2-week pretrial period to one of three oil groups — camelina oil, olive oil, or rapeseed oil — and consumed daily 30 g (actual intake approximately 33 mL) of test oils for 6 weeks. During the intervention, serum LDL cholesterol concentration decreased significantly by 12.2% in the camelina oil group, 5.4% in the rapeseed oil group, and 7.7% in the olive oil group. Camelina oil's serum cholesterol-lowering effect was described as comparable to that of rapeseed and olive oils.

A 2022 randomized, placebo-controlled, double-blind study published in the American Journal of Clinical Nutrition assessed vascular effects. Treated essential hypertensive patients with metabolic syndrome received, during 6 months, either cyclodextrin-complexed camelina oil containing approximately 1.5 g ALA/day (n = 40) or an isocaloric placebo (n = 41). Compared with placebo, camelina oil increased ALA, its elongation product EPA, and the n-9 gondoic acid in erythrocyte membranes. No between-group difference was observed for cardiovascular parameters overall; however, changes in flow-mediated dilation (FMD) were associated with the magnitude of changes in EPA. Compared with placebo, camelina oil increased fasting glycemia and the HOMA-IR index, without affecting plasma lipids, or inflammatory and oxidative stress markers. This mixed result highlights the complexity of interpreting longer-duration studies in metabolically compromised populations.

Evidence strength: Moderate — derived from a meta-analysis of 7 small-to-moderate RCTs (total n = 428). Dose, duration, and population heterogeneity limit definitive conclusions. Effects appear to be dose- and duration-dependent.

5.2 Glycemic Control and Insulin Sensitivity

The evidence for camelina oil's effects on blood glucose and insulin is mixed. Pooled data from four clinical trials demonstrated that camelina oil supplementation did not change fasting blood glucose (−1.86 mg/dl; 95% CI: −6.77, 3.06; I² = 89.0%; P = 0.459) or fasting insulin (−0.10 pmol/L; 95% CI: −0.72, 0.52; I² = 81.1%; P = 0.752) compared to the placebo group.

However, individual trials have shown more specific findings in particular populations. A randomized triple-blind placebo-controlled trial in NAFLD patients (published in International Journal of Clinical Practice, 2021) reported that camelina oil intake led to a significant decrease in insulin concentration (−17.49%), HOMA-IR (−20%), high-sensitive C-reactive protein (hs-CRP) (−12.94%), lipopolysaccharide endotoxin (−32.55%), malondialdehyde (−18.75%), and 8-iso-prostaglandin F2α (−19.55%), and a significant increase in total antioxidant capacity (31.82%) and superoxide dismutase activity (10.22%) in the camelina oil group compared with the placebo group. A total of 46 patients with NAFLD were allocated to either an intervention (20 g/d camelina oil) or placebo (20 g/d sunflower oil) group receiving a calorie-restricted diet for 12 weeks.

In contrast, the longer-duration Bellien et al. (2022) study in hypertensive/metabolic syndrome patients found a less favorable glycemic signal: among hypertensive patients with metabolic syndrome, cyclodextrin-complexed camelina oil compared to placebo for 6 months demonstrated that camelina oil supplementation enhanced fasting glycemia. Since the Bellien study was longer than prior investigations, it appears that long-term camelina oil intake can alter glucose metabolism, and these inconsistent results in the available literature may be due to the different durations of interventions.

Evidence strength: Weak to mixed — high heterogeneity (I² up to 89%) across trials, with inconsistent direction of effect across populations and durations. No definitive conclusion can be drawn about glycemic effects.

5.3 Non-Alcoholic Fatty Liver Disease (NAFLD) and Inflammation

Several RCTs have specifically studied camelina oil in NAFLD populations. The benefits of omega-3 fatty acids have been reported in the management of NAFLD complications; one study evaluated the effects of camelina oil supplementation — as one of the richest dietary sources of omega-3 fatty acids — on glucose homeostasis, inflammation, metabolic endotoxemia, and oxidative stress in NAFLD patients.

A separate co-supplementation RCT (Kavyani et al., 2021, published in Food & Function) studied camelina oil combined with a prebiotic. In this trial, 44 subjects with NAFLD were allocated to either an intervention (20 g/d camelina oil + resistant dextrin) or a placebo (20 g/d camelina oil + maltodextrin) group, receiving a calorie-restricted diet (−500 kcal/d) for 12 weeks. Co-supplementing camelina oil and resistant dextrin significantly decreased insulin concentration, HOMA-IR, hs-CRP, endotoxin, cortisol, the General Health Questionnaire score (GHQ), the Depression, Anxiety and Stress Scale (DASS), and MDA, while increasing total antioxidant capacity and superoxide dismutase in the intervention group compared with the placebo group. Co-supplementing camelina oil and resistant dextrin in combination with a low-calorie diet may improve metabolic risk factors and mental health in NAFLD patients.

Camelina oil enhanced lipid profiles in certain trials while having neutral or negative effects on glycemic control in others.

Evidence strength: Preliminary — small individual RCTs in specific populations (NAFLD) show promising signals for inflammation and oxidative stress, but effect sizes and clinical significance require replication in larger independent trials.

5.4 Lipid Mediator and Anti-Inflammatory Profiles

A randomized controlled trial (NCT01768429) conducted at the University of Eastern Finland examined camelina oil's effects on lipid mediators. Seventy-nine subjects with impaired fasting glucose who completed the controlled dietary intervention were randomized to fatty fish, lean fish, camelina oil (n = 18), or control group for 12 weeks; lipid mediator profiling from fasting plasma samples before and after the intervention was performed by liquid chromatography-mass spectrometry (LC-MS/MS).

The same trial series also examined gene expression. The primary aim of the gene expression sub-study was to examine whether diets enriched in fatty fish, lean fish, or ALA-rich camelina oil differed in their effects on the mRNA expression response of selected inflammation-related genes in peripheral blood mononuclear cells (PBMCs) and subcutaneous adipose tissue (SAT) in subjects with impaired fasting glucose; samples from 72 participants randomized to one of the four 12-week intervention groups were analyzed. The authors proposed that camelina oil intake may partly exert its benefits through immuno-inflammatory molecular regulation in PBMCs.

Evidence strength: Preliminary — mechanistic in vitro and gene expression data are interesting but not sufficient to support clinical health claims without corresponding robust clinical outcome data.

5.5 Serum Fatty Acid Composition Changes

One consistently demonstrated finding across RCTs is that camelina oil consumption reliably enriches circulating ALA levels. A camelina oil-enriched diet improved the serum lipid profile as compared with a diet enriched either in fatty fish or lean fish, in subjects with impaired fasting glucose. Compared with placebo, camelina oil increased ALA, its elongation product EPA, and the n-9 gondoic acid in erythrocyte membranes, confirming bioavailability and metabolic conversion.

5.6 Functional Food Delivery in Older Adults

A randomized placebo-controlled pilot trial examined camelina oil-enriched crackers in an older-adult population. Sixty-six free-living older volunteers aged ≥65 years were enrolled and randomly assigned to either the camelina group or the placebo group; subjects consumed daily 35 g of crackers (camelina-enriched or placebo) twice daily for 12 weeks. In the camelina group, ALA serum concentration was significantly higher (p < 0.01) compared to the placebo group at the end of the study; concerning inflammatory plasma markers, a significant mean pro-inflammatory interleukin-18 plasma concentration decrease in the placebo group compared to the camelina group was observed, but no significant differences in other mean inflammatory marker concentrations post-intervention were noted in either group. A higher (though not statistically significant) reduction of total cholesterol, LDL, and triglycerides in the camelina group was noted post-intervention.

Evidence strength: Weak/pilot-level — a small pilot study; findings are hypothesis-generating only.

6. Body Systems and Health Areas

Cardiovascular System

Camelina oil's ALA content positions it as a food-source omega-3 of interest in cardiovascular research. Human RCTs have assessed effects on serum lipid profiles (LDL, HDL, total cholesterol, triglycerides), vascular function (flow-mediated dilation), and arterial stiffness. Results are mixed and dose/duration-dependent, as detailed in Section 5.1.

Metabolic/Endocrine System

Effects on fasting blood glucose, insulin, and insulin resistance (HOMA-IR) have been studied in RCTs. Results are heterogeneous: some studies in NAFLD patients show improvements in insulin sensitivity, while a 6-month study in hypertensive/metabolic syndrome patients reported increased fasting glycemia. Overall pooled data do not show a statistically significant glycemic effect.

Hepatic System (Liver)

Multiple RCTs have recruited NAFLD patients as the study population, studying effects on oxidative stress biomarkers (MDA, 8-iso-PGF2α), antioxidant capacity (TAC, superoxide dismutase), inflammatory markers (hs-CRP, LPS endotoxin), and metabolic endotoxemia. Findings are encouraging in this population when combined with calorie restriction, but further independent replication is needed.

Immune and Inflammatory Pathways

The competitive relationship between n-6 and n-3 fatty acid metabolism is a central mechanistic framework. There is a competitive relationship between the n-6 and n-3 FA pathways for the use of the Δ5- and Δ6-desaturase and elongase enzymes needed to convert linoleic acid and ALA into longer-chain FAs; consequently, a balanced dietary n-6:n-3 ratio is needed to ensure sufficient conversion to longer-chain FAs in both pathways. Supplementation with camelina oil, which has a naturally favorable n-6:n-3 ratio of approximately 1:2, is hypothesized to shift the balance toward anti-inflammatory eicosanoid production.

Skin and Dermatological Applications

Alpha-linolenic acid is an essential omega-3 fatty acid found in multiple seed oils, including camelina. Both ALA and linoleic acid are described as reducing UV-associated damage and hyperpigmentation of the skin. Camelina oil has been explored as a topical cosmetic ingredient, valued for its fatty acid profile and vitamin E content. Thanks to its moisturising properties and high concentration of vitamin E, an antioxidant, camelina is well-suited for use in skin and hair care. However, robust controlled clinical evidence for topical use specifically in humans is limited.

7. Dosage Forms and Reported Dosages

The following dosages are reported in the scientific literature and are presented descriptively, as reported in each respective source:

• 30 g/day (approximately 33 mL) liquid oil for 6 weeks: Used in a parallel double-blind study in sixty-eight hypercholesterolemic subjects aged 28 to 65 years, randomized to camelina oil, olive oil, or rapeseed oil, who consumed daily 30 g of test oils for 6 weeks.
• 20 g/day for 12 weeks: Used in an RCT in which 46 NAFLD patients were allocated to either an intervention (20 g/d camelina oil) or placebo (20 g/d sunflower oil) group receiving a calorie-restricted diet for 12 weeks.
• 20 g/day for 12 weeks (co-supplementation): In the prebiotic co-supplementation trial, 44 subjects with NAFLD were allocated to either an intervention (20 g/d camelina oil + resistant dextrin) or placebo (20 g/d camelina oil + maltodextrin) for 12 weeks.
• ~1.5 g ALA/day (cyclodextrin-complexed camelina oil) for 6 months: Used in the Bellien et al. double-blind RCT in hypertensive patients with metabolic syndrome (n = 81 total).
• 35 g camelina-enriched crackers twice daily (70 g/day crackers) for 12 weeks: Subjects consumed daily 35 g of crackers (camelina-enriched or placebo) twice daily for 12 weeks.
• Modeled optimal dose — 20 g/day: The meta-analysis concluded that the greatest effect of camelina oil supplementation appears to occur at the dosage of 20 g/day.
• Dosages lower than 30 g/day over more than 8 weeks appear to be where favorable lipid effects are concentrated, based on subgroup analyses of the 2022 meta-analysis.

8. Safety Considerations

General Regulatory Safety Status

Results from chemical analyses (heavy metals, peroxide value) submitted for camelina oil to Health Canada were acceptable; all data provided were adequate to demonstrate that the final product is safe and raises no safety concerns.

Erucic Acid

The most significant documented safety concern for camelina oil is its erucic acid content. The FDA has determined that the maximum allowed limit of erucic acid in edible oils should be less than 2%; exposure to high levels of erucic acid is associated with myocardial lipidosis and heart lesions, which can adversely affect the liver or heart tissues. Camelina oil with a maximum content of 50 g/kg erucic acid is allowed for human consumption, with a tolerable daily intake (TDI) of 7 mg/kg body weight per day. Camelina sativa oil has 1–3% erucic acid; recently, several low-erucic and zero-erucic varieties with erucic acid content of less than 1% have been introduced. The levels of erucic acid in standard camelina oil are below the maximum level (5%) of erucic acid permitted in cooking oils, salad oils, margarines, and shortening as per Canadian Food and Drug Regulations.

Glucosinolates

The potential health benefits of camelina sativa are overshadowed by concerns over high dietary exposure to two anti-nutrient compounds: erucic acid and glucosinolates. Glucosinolate may also have some adverse effects on thyroid function, including enlargement of the thyroid gland. It is important to note that the glucosinolate content is substantially reduced during cold pressing and oil extraction; the oil fraction itself carries far less glucosinolate than the whole seed or seed meal.

Preclinical Toxicology

A non-clinical toxicology study assessed the acute and sub-chronic toxicity of camelina oil in Wistar rats; rats were randomly assigned to groups for acute (14-day) toxicity studies and sub-chronic (90-day) toxicity studies, with the acute study administering camelina oil at a single dose of 5,000 mg/kg body weight. In the sub-chronic study, groups received 250, 500, and 1,000 mg/kg body weight of camelina oil. The study authors noted the need to establish safe dosage parameters for longer-term clinical application. No adverse events have been reported as serious in human RCTs at the doses described in Section 7, though most trials have been short in duration (6–12 weeks) with limited safety reporting.

Oxidative Stability Relative to Other Oils

Camelina oil is more stable than flaxseed oil due to its natural tocopherol (vitamin E) content, but still requires proper handling to maintain its nutritional benefits. The high tocopherol content partially compensates for the oil's high polyunsaturated fatty acid content, which would otherwise predispose it to rapid oxidative degradation.

Brassicaceae Allergy Cross-Reactivity

Because camelina belongs to the Brassicaceae family — which includes mustard, rapeseed, cabbage, and related plants — individuals with documented allergies to other Brassicaceae members or their seed oils should be aware of potential cross-reactivity, though this has not been specifically studied in published clinical literature to date.

Glycemic Considerations in Metabolic Syndrome

A 6-month clinical trial among hypertensive patients with metabolic syndrome demonstrated that camelina oil supplementation enhanced fasting glycemia, and it appears that long-term camelina oil intake can alter glucose metabolism; these inconsistent results in the available literature may be due to the different durations of interventions. This finding warrants attention in populations with pre-existing metabolic conditions or impaired glucose tolerance.

References

• Jalili C, et al. Effects of camelina oil supplementation on lipid profile and glycemic control: a systematic review and dose-response meta-analysis of randomized clinical trials. Lipids in Health and Disease, 2022. PMC9727906.
• Karvonen HM, et al. Effect of alpha-linolenic acid-rich Camelina sativa oil on serum fatty acid composition and serum lipids in hypercholesterolemic subjects. Metabolism, 2002; 51:1253–1260. PubMed PMID 12370843.
• Bellien J, et al. The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome: a randomized, placebo-controlled, double-blind study. American Journal of Clinical Nutrition, 2022; 115(3):694–704.
• Musazadeh V, et al. Omega 3-rich Camelina sativa oil in the context of a weight loss program improves glucose homeostasis, inflammation and oxidative stress in patients with NAFLD: A randomised placebo-controlled clinical trial. International Journal of Clinical Practice, 2021; 75:e14744.
• Kavyani M, et al. Co-supplementation of camelina oil and a prebiotic is more effective for improving cardiometabolic risk factors and mental health in patients with NAFLD: a randomized clinical trial. Food & Function, 2021; 12:8594–8604.
• Topi M, et al. Intake of Camelina Sativa Oil and Fatty Fish Alter the Plasma Lipid Mediator Profile in Subjects with Impaired Glucose Metabolism — A Randomized Controlled Trial. PubMed PMID 32512364.
• The effect of different sources of fish and camelina sativa oil on immune cell and adipose tissue mRNA expression in subjects with abnormal fasting glucose metabolism: a randomized controlled trial. PMC6347599.
• The effect of intakes of fish and Camelina sativa oil on atherogenic and anti-atherogenic functions of LDL and HDL particles: A randomized controlled trial. PubMed PMID 30658192.
• The Effect of Crackers Enriched with Camelina Sativa Oil on Omega-3 Serum Fatty Acid Composition in Older Adults: A Randomized Placebo-Controlled Pilot Trial. PMC10238773.
• Non-clinical Safety Evaluation of Camelina Oil: Acute and 12-Week Oral Toxicities. Iranian Journal of Pharmaceutical Research. PMC11246644.
• Health Canada. Camelina Oil — Novel Food Information. Government of Canada.
• Oxidative Stability of the Oil from Camelina (Camelina sativa L.) Seeds: Effects of Ascorbyl Palmitate Concentrations. Seeds, 2025.
• Wikipedia: Camelina sativa — Botanical and historical overview.
• Interactions between genetics and environment shape Camelina seed oil composition. PubMed PMID 32928104.
• The Enigma of Bioactivity and Toxicity of Botanical Oils for Skin Care. Frontiers in Pharmacology, 2020.
• The effect of dietary camelina, flaxseed, and canola oil supplementation on skin fatty acid profile and immune and inflammatory responses in healthy adult horses. PMC11897893.
• Effects of dietary camelina, flaxseed, and canola oil supplementation on inflammatory and oxidative markers, transepidermal water loss, and coat quality in healthy adult dogs. PMC10034026.
• Nutritional and Metabolic Consequences of Camelina Seed Oil Compared to Flaxseed Oil in a Rat Diet. PMC12250771.
• The effects of Camelina sativa oil and high-intensity interval training on liver function and metabolic outcomes in male type 2 diabetic rats. Frontiers in Nutrition, 2023.
• University of Wisconsin Extension: Winter Camelina — Crops and Soils.